Highly advanced in the clinical development of its glioblastoma treatment, Hemerion initiated a new research project in May with the GIGA Institute at the University of Liège. The objective is to validate the effectiveness of Hemerion’s technology on radioresistant tumor cells: a major challenge for improving the treatment of many other cancers.
Hemerion began a research project in May with the Giga Institute at the University of Liège in Belgium. Located on the campus of the Liège university hospital, this biomedical research institute brings together more than 600 scientists, doctors, pharmacists, veterinarians, psychologists, biologists, chemists, physicists, mathematicians, and engineers from 45 different nationalities. It is a major player in therapeutic innovation in Europe, with over 100 patents filed.
The project aims to explore new avenues for improving Hemerion’s technology in the treatment of solid tumors, particularly its ability to selectively target and destroy radioresistant tumor cells. Safe for healthy cells, Hemerion’s technology could evolve the standard of care by limiting the need for radiotherapy, whose side effects on healthy tissues negatively impact patients’ quality of life.
In vitro stem cell illumination experiment
The research is based on the institute’s teams’ expertise in neurology and immuno-oncology.
The project is led by Dr. Mélanie Rose, Research Scientist and immuno-oncology specialist at Hemerion, and by Professor Bernard Rogister, Dr. Arnaud Lombard, and Dr. Virginie Neirinckx for the Giga Institute.